Risk assessment for a first stroke in Spanish hypertensive population in primary care. The ERIC-HTA study;Evaluación del riesgo de un primer ictus en la población hipertensa española en atención primaria. Estudio ERIC-HTA

Medicina Clinica

Volumn 125, Issue 7, 2005, Pages 247-251

  Lozano, José V ^a   Redón, Josep ^b   Cea Calvo, Luis ^c   Fernández Pérez, Cristina ^d   Navarro, Jorge ^a   Bonet, Álvaro ^a   González Esteban, Jorge ^c  

^a Centro de Salud Nazaret   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Medical affairs Merck sharp and Dohme ltd   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Hypertension; Risk; Stroke

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CORONARY RISK; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; FEMALE; FRAMINGHAM SCALE; GENDER; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; RATING SCALE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SPAIN; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 25144498528     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078099     Document Type: Article

References (31)

1. Banegas JR, Rodríguez-Artalejo R, De la Cruz JJ, De Andrés B, Rey J. Mortalidad relacionada con la hipertensión y la presión arterial en España. Med Clin (Barc). 1999;112:489-94.
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA. 2003;289:2560-72.
3. 2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens. 2003;21:1011-53.
4. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Meaton J, et al. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure. Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;355:765-74.
5. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
6. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
7. Lewis ED, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
8. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
9. Coca A. Control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001. Hipertensión. 2002;19:390-9.
10. Llisterri JL, Rodríguez-Roca GC, Alonso FJ, Lou S, Divisón JA, Santos JA, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRES-CAP 2002. Med Clin (Barc). 2004;122:165-71.
11. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-6.
12. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
13. Instituto Nacional de Estadística. [Consultado: 23 de abril de 2004]. Disponible en: hhtp://www. ine.es/prensa/np313.pdf
14. Regidor E, Gutiérrez-Fisac JL, CaIIe ME, Otero A. Patrón de mortalidad en España, 1998. Med Clin (Barc). 2002;118:13-5.
15. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, et al. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke. 1997;28:1507-17.
16. D'Agostino R, Wolf PA, Belanger A, Kannel W. Stroke risk profile: adjustment for antihipertensive medication. The Framingham Study. Stroke. 1994;25:40-3.
17. Álvarez J, Coca A, De la Figuera M, Lozano JV, Redón J, Ruiz N, et al. Reducción del riesgo de ictus en el paciente hipertenso. Valencia: Actas del Congreso de la SEHLELHA; marzo 2003.
18. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
19. Kjeldsen S, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Pressure. 2001;10:190-2.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
21. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31.
22. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-44.
23. Barrios V, Campuzano R, Peña G, Guzmán G, Ruilope LM. Estratificación del riesgo cardiovascular en hipertensión en atención primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC. Hipertensión. 2002;19:114-20.
24. Martínez MA, Sancho T, Armada E, Rubio JM, Antón JL, Torre A, et al. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. Am J Hypertens. 2003;16:556-63.
25. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-93.
26. Dalfó A, Bayo J, Gil M, Campillo M, Botey A, Vila MA, et al. Hipertrofia venticular izquieda en una población hipertensa general de Barcelona. Med Clin (Barc). 1995;105:361-6.
27. Coca A, Gabriel R, De la Figuera M, López-Sendón JL, Fernández R, Sagastagoitia JD, et al. The impact of different echocardiographic diagnostic criteria on the prevalence of left ventricular hypertrophy in essential hypertension: the VITAE study. J Hypertens. 1999;17:1471-80.
28. Aranceta J, Pérez Rodrigo C, Serra Majem L, Ribas L, Quiles Izquierdo J, Vioque J, et al. Prevalencia de la obesidad en España: resultados del estudio SEEDO 2000. Med Clin (Barc). 2003;120:608-12.
29. Aranceta J, Pérez-Rodrigo C, Serra-Majem L, Ribas L, Quiles-Izquierdo J, Vioque J, et al. Influence of sociodemographic factors in the prevalence of obesity in Spain. The SEEDO'97 Study. Eur J Clin Nutr. 2001;55:430-5.
30. Coca A. Control de la hipertensión arterial en España. Resultados del estudio Controlpres 95. Hipertension. 1995;12:182-8.
31. Coca A. Control de la hipertensión arterial en España. Resultados del estudio Controlpres 98. Hipertensión. 1998;15:298-307.